Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy
3
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Purpose: To compare the effectiveness of intravitreal injections of bevacizumab and ranibizumab in patients with treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: Records from 106 consecutive patients who received intraviteral bevacizumab (n = 58, 1.25 mg) or ranibizumab (n = 52, 0.5 mg) for treatment of PCV were retrospectively reviewed. After three initial monthly loading injections, injection was performed as needed. The main outcome measures included best-corrected visual acuity (BCVA), foveal central thickness (FCT) as assessed by spectral domain optical coherence tomography,and the changes in polypoidal lesions based on an indocyanine green angiography. Results: The average number of injections was 3.31 ± 1.25 in the bevacizumab group and 3.44 ± 0.92 in the ranibizumab group. Mean logarithm of the minimum angle of resolution of BCVA from baseline to 6 months after injection improved by 0.17 in the bevacizumab group (p = 0.03) and by 0.19 in the ranibizumab group (p = 0.01). Average FCT decreased from 322 ± 62.48 μm to 274 ± 40.77 μm in the bevacizumab group (p = 0.02)and from 338 ± 50.79 μm to 286 ± 36.93 μm in the ranibizumab group (p = 0.02). Polyp regression rate was 20.7% (12 of 58 eyes) in the bevacizumab group and 21.2% (11 of 52 eyes) in the ranibizumab group. There was no statistically significant difference between groups in BCVA improvement achieved, FCT improvement achieved, and polyp regression rate between groups. Conclusions: Intravitreal injections of bevacizumab and ranibizumab have similar effects in stabilizing of visual acuity, macular edema, and regression of polypoidal complex in PCV eyes over the short term.
Abstract
Purpose: To compare the effectiveness of intravitreal injections of bevacizumab and ranibizumab in patients with treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: Records from 106 consecutive patients who received intraviteral bevacizumab (n = 58, 1.25 mg) or ranibizumab (n = 52, 0.5 mg) for treatment of PCV were retrospectively reviewed. After three initial monthly loading injections, injection was performed as needed. The main outcome measures included best-corrected visual acuity (BCVA), foveal central thickness (FCT) as assessed by spectral domain optical coherence tomography,and the changes in polypoidal lesions based on an indocyanine green angiography. Results: The average number of injections was 3.31 ± 1.25 in the bevacizumab group and 3.44 ± 0.92 in the ranibizumab group. Mean logarithm of the minimum angle of resolution of BCVA from baseline to 6 months after injection improved by 0.17 in the bevacizumab group (p = 0.03) and by 0.19 in the ranibizumab group (p = 0.01). Average FCT decreased from 322 ± 62.48 μm to 274 ± 40.77 μm in the bevacizumab group (p = 0.02)and from 338 ± 50.79 μm to 286 ± 36.93 μm in the ranibizumab group (p = 0.02). Polyp regression rate was 20.7% (12 of 58 eyes) in the bevacizumab group and 21.2% (11 of 52 eyes) in the ranibizumab group. There was no statistically significant difference between groups in BCVA improvement achieved, FCT improvement achieved, and polyp regression rate between groups. Conclusions: Intravitreal injections of bevacizumab and ranibizumab have similar effects in stabilizing of visual acuity, macular edema, and regression of polypoidal complex in PCV eyes over the short term.
참고문헌 (21)
- Yannuzzi LA, "Idiopathicpolypoidal choroidal vasculopathy (IPCV)", Retina, 10, pp.1~82 (1990)
- Yannuzzi LA, "The expandingclinical spectrum of idiopathic polypoidal choroidal vasculopathy", Arch Ophthalmol, 115, pp.478~485 (1997)
- Sho K, "Polypoidal choroidalvasculopathy: incidence, demographic features, and clinicalcharacteristics", Arch Ophthalmol, 121, pp.1392~1396 (2003)
- Spaide RF, "Indocyaninegreen videoangiography of idiopathic polypoidal choroidalvasculopathy", Retina, 15, pp.100~110 (1995)
- Chan WM, "Photodynamic therapywith verteporfin for symptomatic polypoidal choroidalvasculopathy: one-year results of a prospective case series", Ophthalmology, 111, pp.1576~1584 (2004)
- Gomi F, "One-year outcomes ofphotodynamic therapy in age-related macular degenerationand polypoidal choroidal vasculopathy in Japanese patients", Ophthalmology, 115, pp.141~146 (2008)
- Akaza E, "Role of photodynamictherapy in polypoidal choroidal vasculopathy", Jpn JOphthalmol, 51, pp.270~277 (2007)
- Gomi F, "Efficacy of intravitrealbevacizumab for polypoidal choroidal vasculopathy", Br J Ophthalmol, 92, pp.70~73 (2008)
- Lai TY, "Intravitreal bevacizumab(Avastin) with or without photodynamic therapy for thetreatment of polypoidal choroidal vasculopathy", Br J Ophthalmol, 92, pp.661~666 (2008)
- Cho M, "Refractory neovascularage-related macular degeneration secondary to polypoidalchoroidal vasculopathy", Am J Ophthalmol, 148, pp.70~78 (2009)
- Tong JP, "Aqueous humor levelsof vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathyand choroidal neovascularization", Am J Ophthalmol, 141, pp.456~462 (2006)
- Kokame GT, "Continuous anti-VEGFtreatment with ranibizumab for polypoidal choroidal vasculopathy:6-month results", Br J Ophthalmol, 94, pp.297~301 (2010)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-relatedmacular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- Matsuoka M, "Expression of pigmentepithelium derived factor and vascular endothelialgrowth factor in choroidal neovascular membranes andpolypoidal choroidal vasculopathy", Br J Ophthalmol, 88, pp.809~815 (2004)
- Gomi F, "Polypoidal choroidal vasculopathy andtreatments", Curr Opin Ophthalmol, 19, pp.208~212 (2008)
- Lantry LE, "Ranibizumab, a mAb against VEGF-A forthe potential treatment of age-related macular degenerationand other ocular complications", Curr Opin Mol Ther, 9, pp.592~602 (2007)
- Shahar J, "Electrophysiologicand retinal penetration studies following intravitreal injectionof bevacizumab (Avastin)", Retina, 26, pp.262~269 (2006)
- Mordenti J, "Comparisonsof the intraocular tissue distribution, pharmacokinetics,and safety of 125I-labeled full-length and Fab antibodiesin rhesus monkeys following intravitreal administration", Toxicol Pathol, 27, pp.536~544 (1999)
- Kuroiwa S, "Pathological featuresof surgically excised polypoidal choroidal vasculopathymembranes", Clin Experiment Ophthalmol, 32, pp.297~302 (2004)
- Okubo A, "Clinicopathologicalcorrelation of polypoidal choroidal vasculopathyrevealed by ultrastructural study", Br J Ophthalmol, 86, pp.1093~1098 (2002)
- Hirami Y, "Hemorrhagic complicationsafter photodynamic therapy for polypoidal choroidalvasculopathy", Retina, 27, pp.335~341 (2007)